drugset / Trial / NCT02458716
Cytoreductive Prostatectomy in Treating Patients With Newly Diagnosed, Metastatic Prostate Cancer
Phase 1
Completed
26 enrolled
Rutgers, The State University of New Jersey
National Cancer Institute (NCI) · collabRutgers Cancer Institute of New Jersey · collab
NaSingle-groupOpen-labelTreatment
Summary
This phase I trial studies the side effects of cytoreductive prostatectomy in treating patients with newly diagnosed prostate cancer that has spread from the primary site to other places in the body. Cytoreductive prostatectomy is a type of surgery that removes the prostate and as much of the tumor as possible. When combined with hormone therapy, robotic assisted radical prostatectomy (RARP) or conventional open retropubic radical prostatectomy (RRP) may prolong survival in patients with prostate cancer that has spread.
Timeline
- Start
- 2015-03-06
- Primary completion
- 2020-01-14
- Completion
- 2020-01-14
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Background | Bicalutamide | Other / unclassified | — | — |
| Background | Leuprolide | Other / unclassified | — | — |